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Alginate calcification has been previously reported clinically and during animal implantation; however
no study has investigated the mechanism, extensively characterized the mineral, or evaluated multiple
methods to regulate or eliminate mineralization. In the present study, alginate calcification was first
studied in vitro: calcium-crosslinked alginate beads sequestered surrounding phosphate while forming
traces of hydroxyapatite. Calcification in vivowas then examined in nude mice using alginate microbeads
with and without adipose stem cells (ASCs). Variables included the delivery method, site of delivery, sex
of the animal, time in vivo, crosslinking solution, and method of storage prior to delivery. Calcium-
crosslinked alginate microbeads mineralized when injected subcutaneously or implanted intramuscu-
larly after 1e6 months. More extensive analysis with histology, microCT, FTIR, XRD, and EDS showed
calcium phosphate deposits throughout the microbeads with surface mineralization that closely
matched hydroxyapatite found in bone. Incorporating 25 mM bisphosphonate reduced alginate calcifi-
cation whereas using barium chloride eliminated mineralization. Buffering the crosslinking solution with
HEPES at pH 7.3 while washing and storing samples in basal media prior to implantation also eliminated
calcification in vivo. This study shows that alginate processing prior to implantation can significantly
influence bulk hydroxyapatite formation and presents a method to regulate alginate calcification.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Alginate hydrogels have been used for a wide variety of tissue
engineering and regenerative medicine applications because they
have favorable mass transfer properties [1], can be molded into
specific shapes [2,3], have adjustable degradation kinetics [4e6],
support a range of different cell phenotypes [7e9], can be
mechanically and biochemically modified [10e12], support cell
differentiation in large animal models [13], and are biocompatible
for delivery of cells in human trials [14]. The most commonmethod
of incorporating bioactive molecules or cells into alginate matrices
is via extrusion, in which an alginate suspension is extruded
through a needle to form droplets that fall into a solution that
contains divalent cations causing alginate crosslinking [8,15e17].: þ1 404 894 2291.
.D. Boyan).
All rights reserved.Alginate microspheres can also be created by using air flow [18] or
high electrostatic potentials [19] to overcome surface tension, and
have been used to encapsulate and deliver pancreatic islets [8]. In
addition to cell delivery, hydrogel microspheres have generally
been used for spheroid cell culture, drug delivery, and as injectable
tissue fillers. The ability of alginate microspheres as an injectable
filler to deliver encapsulated cells has not been fully characterized,
and, to further develop this technology, the mass transfer proper-
ties and reabsorption kinetics of alginate microspheres must be
controllable in vivo.
Various pre-clinical and clinical studies have reported alginate
calcification [20e22], which presents a critical challenge in devel-
oping large scale applications using this hydrogel. Our preliminary
studies have shown that alginate microbeads calcify in vivo, which
affects mass transfer in and out of the hydrogel while preventing
reabsorption and creating unwanted mineralization foci within the
tissue. Therefore, it would be advantageous to develop methods to
prevent alginate calcification. However, if alginate calcification can
C.S.D. Lee et al. / Biomaterials 31 (2010) 4926e4934 4927be regulated temporally and spatially in vivo, this hydrogel could
also be used as a stimulus for in situ bone repair and formation. To
achieve this type of application, a thorough understanding of the
mechanism of alginate calcification and methods to control it need
to be developed. No study, however, has yet extensively charac-
terized alginate calcification nor has any study thoroughly inves-
tigated methods to control this process.
The objective of this study was to investigate how alginate beads
calcify and to develop different methods to control alginate calcifi-
cation while characterizing the mineral formed. We first hypothe-
sized that calcium-crosslinked alginate calcifies by sequestering the
surrounding phosphate to form calcium phosphate. Alginate beads
were cultured in a phosphate solution, and phosphate content and
subsequent mineralization were analyzed. We then hypothesized
that calcium-crosslinked alginate has the ability to calcify in vivo
regardless of the presence of encapsulated cells, delivery method,
site of delivery, or sex of the animal. Alginate microbeads seeded
with or without human adipose stem cells were implanted intra-
muscularly or injected subcutaneously in male and female nude
mice and the retrieved implants analyzed for mineral content and
properties. Finally, we hypothesized that the type of mineral would
be similar to hydroxyapatite found in bone and that this calcification
could be eliminated by varying divalent cations used to crosslink
alginate or by buffering the pH in the beads before implantation.
Barium was used as a crosslinking ion since it does not readily
interact with phosphate ions [23] whereas alendronate was added
since it is a bisphosphonate that chelates calcium and attaches
strongly to hydroxyapatite to prevent crystal growth [24]. HEPES, an
organic zwitterion buffering agent that does not contain phosphate,
was used to buffer the crosslinking bath below physiological levels
since hydroxyapatite crystals are stable to neutral to alkaline envi-
ronments [25]. Implanted alginate microbeads created in different
crosslinking solutions were retrieved and extensively characterized.
2. Materials and methods
2.1. In vitro phosphorus content
To test our first hypothesis that calcium-crosslinked alginate calcifies by
sequestering surrounding phosphate, an in vitro study was designed to assess the
ability of calcium-crosslinked alginate to sequester phosphate. Low viscosity sodium
alginate [Kelco Corp., Chicago, IL, USA] dissolved in 155 mM sodium chloride at
a concentration of 12 mg/ml was dropped gently through a 25 gauge needle at a rate
of 2e3 drops per second into a 102 mM calcium chloride bath. After 10 min, the
beads (15e20 beads/10 ml alginate) were washed four times with 155 mM NaCl. The
beads were suspended in 25 ml 4 mM (NH4)2HPO4 in 0.05 M Tris buffer at pH 7.4, and
removed at different time points over a 4 h period (0, 0.5, 1, 2, and 4 h). After
incubation at room temperature, the beads were collected by centrifugation, and the
supernatants were assayed for phosphorus content using a commercially available
kit [Sigma, St. Louis, MO, USA] (n ¼ 3 for each experimental group and time). Beads
were then lyophilized, mixed with KBr (w1 wt%), and made into KBr pellets for
Fourier transform infrared spectroscopy (FTIR) analysis as outlined below. In some
cases, the cloudy supernatant of the incubation buffer was centrifuged to a pellet,
washed with acetone, air dried, and analyzed as a KBr pellet via FTIR.
2.2. Cell isolation and culture
To test our second hypothesis that calcium-crosslinked alginate microbeads
with and without cells would calcify in vivo, adipose stem cells (ASCs) were isolated.
Fat was excised from male and female patients less than 18 years of age undergoing
cosmetic and reconstructive procedures at Children's Healthcare of Atlanta under an
approved IRB protocol at Georgia Institute of Technology and Children's Healthcare
of Atlanta. All patients and parents gave written consent to both the procedure and
handling of fat thereafter. ASCs were isolated via a collagenase digestion solution as
previously described [26]. Cells were then seeded at 5000 cells/cm2 and cultured in
Lonza Mesenchymal Stem Cell Growth Medium [Lonza, Basel, Switzerland] up to
second passage.
2.3. Alginate bead and microbead fabrication
To test our hypotheses that alginate calcification can occur independently of
how and where microbeads were implanted and that it could be eliminated byvarying the crosslinking method, alginate microbeads were made in different
crosslinking solutions. Medium molecular weight alginate (240,000 kDa) with
a high guluronate to mannuronate ratio (69% guluronate) [FMC Biopolymer,
Drammen, Norway] was UV light sterilized and dissolved in 155mM sodium chloride
[Ricca Chemical, Arlington, TX, USA] at a concentration of 20 mg/ml. Alginate con-
taining ASCs was initially seeded at 1106 cells/ml, resulting in a final measured cell
number of 40  7 cells per microbead (Fig. 2B). Microspheres were created using
a Nisco Encapsulator VAR V1 LIN-0043 [Nisco Engineering AG, Zurich, Swizterland]
at a 4 ml/h flow rate, 0.175 mm nozzle inner diameter, and 6 kV electrostatic
potential [27]. Microbeads were made in four different crosslinking solutions:
(i) 50 mM CaCl2 and 150 mM glucose (non-buffered); (ii) 50 mM CaCl2 and 150 mM
glucose with 25 mM alendronate [Sigma] (bisphosphonate); (iii) 20 mM BaCl2 and
150 mM glucose (barium); and (iv) 50 mM CaCl2 and 150 mM glucose with 15 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid at pH 7.3 [Sigma] (HEPES-
buffered). Microbeads made in non-buffered crosslinking solutions were washed
and stored in 155 mM sodium chloride (saline) while microbeads made in the
HEPES-buffered crosslinking solution were washed and stored in Dulbecco's
modified eagle medium (DMEM) [Invitrogen, Carlsbad, CA, USA] at 37 C and 5% CO2
prior to implantation to allow for longer term storage of ASC microbeads in future
studies. Following microencapsulation, microbeads were implanted as described
below.
2.4. Cell viability
To determine whether ASCs were viable after microencapsulation in alginate
and remained viable after injection delivery, microencapsulated ASCs suspended in
DMEMwere injected as described below and cultured for 0, 1, and 2 weeks in Lonza
Mesenchymal Stem Cell Growth Medium. Microencapsulated ASCs that were not
injected were also cultured for comparison (n ¼ 6 for each experimental group
and time). Viability was measured using fluorescent confocal microscopy using
a LIVE/DEADViability Kit following the manufacturer's protocol [Invitrogen]. Briefly,
samples were incubated for 30 min in a PBS solution containing 10 mM CaCl2, 4 mM
ethidium homodimer-1, and 2 mM calcein and imaged with a LSM 510 confocal
microscope [Carl Zeiss MicroImaging Inc., Thornwood, NY].
2.5. Animal surgeries
Male and female athymic nude (Nu/Nu) micewere housed in the vivarium in the
Institute for Bioengineering and Bioscience at the Georgia Institute of Technology
and handled under a protocol approved by the IACUC committee. Prior to surgeries,
athymicmicewere anesthetized using isoflurane gas. Both non-buffered and HEPES-
buffered microbeads were directly implanted subcutaneously or intramuscularly or
injected subcutaneously to determine if delivery method affected alginate calcifi-
cation. Bisphosphonate and barium microbeads were only injected subcutaneously
to reduce animal discomfort and to investigate how the crosslinking solution affects
alginate calcification. For intramuscular implants, a small skin incision was made
over the calf region of the hind limb, a pouch was prepared in the muscle by blunt
dissection, and approximately 0.1 ml microbeads were inserted directly into the
gastrocnemius muscle [28]. For all subcutaneous injections, 0.25 ml microbeads
were mixed in 0.25 ml DMEM and injected via an 18 gauge needle. Animals were
euthanized by CO2 inhalation at various time points from 1 to 6months. Each animal
received either 2 injections or 2 implantations subcutaneously or 2 bilateral intra-
muscular implantations (n ¼ 4e6 for each experimental condition). Samples were
harvested and processed for subsequent studies as described below.
2.6. Micro-computed tomography
To assess the extent of alginate microbead mineralization, subcutaneous and
intramuscular samples were excised from nude mice, immediately scanned using
a mCT 40 (Scanco Medical, Switzerland) with a voxel size of 20 mm, and analyzed as
previously described [29]. Calcification was identified using a fixed threshold;
individual samples were isolated with user-guided contours and three-dimensional
images were created. Samples were then fixed in 10% neutral buffered formalin
[Sigma] for histological processing or frozen and lyophilized for subsequent mate-
rials characterization.
2.7. Histology
After 48 h of fixation in formalin, representative undecalcified samples were
embedded in plastic, and cut into 10-mm thick sections. Samples were stained with
von Kossa with a nuclear fast red counter stain as previously described [30].
2.8. Fourier transform-infrared spectroscopy (FTIR)
To test our hypothesis that alginate calcification mineral was similar to
hydroxyapatite found in bone, infrared spectroscopy in attenuated total internal
reflection (ATR) mode [Pike Technologies, Madison, WI, USA] was performed on
lyophilized samples using a Nexus 870 FTIR bench [Nicolet Instrument Corporation,
C.S.D. Lee et al. / Biomaterials 31 (2010) 4926e49344928Madison, WI, USA]. Each spectrumwas the mean of two acquisitions (between 1800
and 800 cm1) of at least 64 scans with a spectral resolution of 4 cm1.
2.9. X-ray diffraction
Crystal structure of the samples was identified using an X'Pert PRO Alpha-1
diffractometer [PANalytical, Almelo, The Netherlands]. X-ray diffraction (XRD) scans
were collected using Cu Ka radiation. A 1 parallel plate collimator, ½ divergence slit
and 0.04 rad soller slit were used for controlled axial divergence. BraggeBrentano
parafocusing at 45 kV and 40 mA was used to analyze samples. The assignment of
detected peaks to crystalline phases was performed using the database from the
International Centre for Diffraction Data (ICDD, 2008).
2.10. Scanning electron microscopy and energy dispersive X-ray spectroscopy
Morphology of the microbeads was qualitatively evaluated using an Ultra 60
field emission scanning electron microscope (FESEM) [Carl Zeiss SMT Ltd., Cam-
bridge, UK] at an accelerating voltage of 5 kV and different magnifications. Chemical
composition of samples was determined using an INCAPentaFET-x3 energy
dispersive X-ray spectrometer (EDS) [Oxford Instruments, Bucks, UK] at an accel-
erating voltage of 15 kV and a working distance of 8.5 mm.
3. Results
3.1. In vitro calcification
Upon adding the calcium-crosslinked alginate beads to the
phosphate buffer, the solution started to become cloudy. The phos-
phate concentration in the bath decreased by 20e35% over the firstFig. 1. In vitro study. (A) Phosphate concentration of buffered bath over time for different a
(n ¼ 3 for each experimental group and time). FTIR spectra of (B) lyophilized alginate bead4h anddependedon the amount of alginate thatwas added (Fig.1A).
The FTIR spectrum of the lyophilized alginate had peaks between
1600 and 1800 cm1,1370e1525 cm1, and 900e1200 cm1 (Fig.1B)
while the FTIR spectrum of the phosphate bath pellet had a similar
peak between 900 and1200 cm1 alongwith peaks centered around
1600 and1400 cm1 (Fig.1C). Pure hydroxyapatite had characteristic
peaks between 1400 and 1550 cm1 and 900e1200 cm1 (Fig. 1D).
3.2. Visualization of in vivo calcification
Microbeads formed in all crosslinking solutions ranged from 200
to 350 mm in diameter (Fig. 2A). When non-buffered microbeads
were either implanted or injected subcutaneously into male nude
mice, almost every sample showed the presence of mineral at all
time points examined (1, 3, and 6 months; Table 1). Specifically, 24
of 24 implanted samples calcifiedwhereas 21 of 24 injected samples
calcified. ASC viability prior to implantation or injectionwas 70 3%
(Fig. 2B), and in vitro studies show cell viability increasing to 80 5%
twoweeks post-injection (data not shown), yet the presence of ASCs
had no apparent effect on mineralization (Table 1). Mineralization
was demonstrated by light microscopy (Fig. 2C) or by visual
inspection of implanted (Fig. 2D) and injected (Fig. 2E) microbeads.
Modifications to the crosslinking protocol reduced or eliminated
calcification as detected by von Kossa staining (Table 2). When
microbeads were injected subcutaneously, no visual calcificationmounts of alginate added to 25 ml of 4 mM (NH4)2HPO4 in 0.05 M Tris buffer at pH 7.4
s, (C) precipitate from the bath, and (D) pure hydroxyapatite.
Fig. 2. Gross-visualization of alginate microbead mineralization. (A) Microbeads before implantation or injection under a light microscope (Bar ¼ 100 mm). (B) Live/dead staining of
human ASCs within a single microbead post-injection (Bar ¼ 25 mm) (C) Visualization of mineralized microbeads 3 months post-implantation under a light microscope
(Bar ¼ 100 mm). (D) Mineralized microbeads 3 months post-implantation. (E) Mineralized microbeads 1 month post-injection.
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the addition of the 25 mM bisphosphonate to the crosslinking
solution partially reduced mineralization. HEPES-buffered (pH 7.3)
microbeads injected subcutaneously also had no apparent calcifi-
cation. When HEPES-buffered samples were then directly implan-
ted subcutaneously and intramuscularly, there was no visual
mineralization. In contrast, when non-buffered microbeads were
implanted a second time, all the subcutaneous and two-thirds of
the intramuscular samples mineralized.
The intensity of vonKossa staining for phosphatewas very strong
in non-buffered samples as phosphate was present throughout
almost every microbead (Fig. 3A). Barium chloride-treated samples
had no detectable presence of von Kossa staining with microbeads
surrounded by endothelial tissue (Fig. 3B). Bisphosphonate-treated
samples that did calcify only had partially positive staining for
phosphate as both the intensity of staining and the number of
positively stained microbeads was lower compared to non-buffered
samples (Fig. 3C, Table 2). HEPES-buffered samples had no von Kossa
staining and were surrounded by connective tissue (Fig. 3D).
Cross-sectional X-ray sections of non-buffered samples via
microCT showed extensive mineralization that was not just limited
to the surfaces of individual microbeads or peripheral microbeads
of the bolus (Fig. 4A and B). Additionally, the intensity of X-ray
attenuation seemed to be comparable to the adjacent bone. 3-DTable 1
Mineralization of cellular and acellular microbeads in male nude mice with different
delivery methods at different times subcutaneously based on visual inspection.
Months Post Op Empty ASC-seeded
1 Implantation: 4/4 Mineralized Implantation: 4/4 Mineralized
Injection: 3/4 Mineralizeda Injection: 3/4 Mineralized
3 Implantation: 4/4 Mineralized Implantation: 4/4 Mineralized
Injection: 3/4 Mineralizeda Injection: 4/4 Mineralized
6 Implantation: 4/4 Mineralized Implantation: 4/4 Mineralized
Injection: 4/4 Mineralized Injection: 4/4 Mineralized
a Microbeads for one sample disappeared and had no volume retention.reconstructions further demonstrate the extent of calcification of
both subcutaneous (Fig. 4C) and intramuscular (Fig. 4D) samples.
HEPES-buffered samples were undetectable by microCT (data not
shown).
3.3. Characterization of in vivo calcification
Comparison of FTIR spectra of the lyophilized explanted
samples presented significant differences. The spectrum of the
non-buffered sample (Fig. 5A) showed the characteristic bands of
hydroxyapatite around 1400e1550 cm1 and 900e1200 cm1 and
corresponded well with the spectrum of the pure hydroxyapatite
powder. The spectrum of the HEPES-buffered sample (Fig. 5B) had
no traces of the HEPES spectrum (Fig. 5C), but matched almost
perfectly with the spectrum of the pure alginate powder (Fig. 5D).
No presence of hydroxyapatite was noted in the HEPES-buffered
sample.
The XRD spectra of the explanted samples showed the presence
of monphasic crystalline structures (Fig. 6). The alginate powder
presented no diffraction pattern. The non-buffered sample
appeared to have the crystal structure of hydroxyapatite, whereas
the HEPES-buffered sample showed themain peaks of NaCl crystals
and incorporated none of the peaks of the HEPES buffer. The
crystalline structures were further confirmed with the EDS spectraTable 2
Attempts to regulating calcification by modifying the crosslinking solution and
delivery location 5e8 weeks post-implantation or injection based on von Kossa
staining.
Non-buffered Barium Bisphosphonate HEPES-Buffered
Implantation Subcutaneous:
4/4 Calcified
e e Subcutaneous:
0/4 Calcified
Intramuscular:
4/6 Calcified
e e Intramuscular:
0/4 Calcified
Injection e 0/4
Calcified
2/4
Calcified
0/4 Calcified
Fig. 3. Histology of in vivo microbeads. von Kossa with nuclear fast red counter stain to determine calcification for representative (A) non-buffered, (B) barium chloride,
(C), bisphosphonate, (D) buffered samples in vivo after 2 months. Bar represents 100 mm for all images.
C.S.D. Lee et al. / Biomaterials 31 (2010) 4926e49344930(Table 3), which showed the presence of 10.2  1.3% Ca and
6.3  0.8% P on the non-buffered sample (Ca/P ratio of 1.6  0.4),
and only approximately 1% of each on the HEPES-buffered sample.
Conversely, the HEPES-buffered sample included 14.3  0.7% Na
and 13.2 1.8% Cl, and the non-buffered sample had<1% of Na and
no traces of Cl. Themain components of both samples were C and O,
primarily from the alginate polymer. SEM image of non-buffered
microbeads that were lyophilized shows an intact spherical struc-
ture with surrounding tissue growth (Fig. 7A) whereas HEPES-
bufferedmicrobeads that were lyophilizedwere clearly fragmented
(Fig. 7B).
4. Discussion
Alginate mineralization has been sporadically reported when
used for biomedical research and clinical applications [20e22].
The presence of such calcifications hinders soft tissue regenera-
tion; therefore, effective strategies are needed to eliminate algi-
nate calcification. This study is the first to characterize the
mineralization that occurs, propose a mechanism behind alginate
calcification, and develop strategies to modulate alginate calcifi-
cation. It appears that alginate calcification both in vitro and in vivo
occurs due to the alginate hydrogel providing a bolus of calcium
ions that then interacts with surrounding phosphate ions to form
calcium phosphate salts. This finding is confirmed by our in vitro
results in which phosphate is sequestered from the solution intothe alginate and by our in vivo results where alginate crosslinked
with barium e a divalent cation that does not readily interact with
phosphate ions [23] e exhibited no mineralization, and the addi-
tion of alendronate e a bisphosphonate that prevents crystal
growth at concentrations as low as 106 M [24] e reduced calcifi-
cation. Although bariumwas effective at preventing calcification, it
is known to be toxic at high levels [31] and hinders the ability for
alginate to reabsorb while it significantly retards the delivery of
soluble proteins [23]. Despite the alendronate's partial effective-
ness, bisphosphonates are known to have a wide variety of side
effects when treating osteoporosis [32] and have been shown to
influence differentiation of stem cells [33]. Therefore, another
method of regulating calcification induced by the alginate beads
was investigated.
Hydroxyapatite crystals are stable to neutral to alkaline envi-
ronments [25]. Therefore it was believed that buffering the pH of
alginate hydrogels slightly below physiological levels with a non-
phosphate buffer would help eliminate calcification in vivo while
minimizing any biological side effects. HEPES was selected because
it does not contain phosphate, is commonly used in cell culture, and
is also effective for maintaining enzyme structure and function
below physiological temperatures [34]. Additionally, instead of
washing and storing microbeads in saline, which is the standard
care for most medical implants, DMEMwas used to allow for longer
term storage of microbeads with encapsulated cells. MicroCT
imaging along with von Kossa staining of precipitated phosphate
Fig. 4. MicroCT analysis of non-buffered in vivo samples. (A) Representative X-ray cross-section of subcutaneously implanted non-buffered microbeads after 5 weeks in vivo. (B) 3-D
reconstruction of subcutaneously implanted non-buffered microbeads after 5 weeks in vivo. (C) Representative sagittal X-ray cross-section of intramuscularly implanted non-
buffered microbeads near the tibia after 5 weeks in vivo. (D) 3-D reconstruction of intramuscular implanted non-buffered microbeads along with the tibia after 5 weeks in vivo. Bar
represents 1 mm for all images.
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samples whereas buffering with HEPES and maintaining the pH of
the crosslinking solution to pH 7.3, along with washing and storing
samples in DMEM, completely eliminated mineralization. Both
microCT and histology showed that calcification was not limited to
just the surface, suggesting that the calcium crosslinks throughout
the microbeads play a major role in alginate calcification.
Further investigation using FTIR, XRD, and EDS showed that
hydroxyapatite is the most stable crystal phase formed when
alginate is calcified. Explanted non-buffered alginate microbeads
had similar spectra to pure hydroxyapatite for both FTIR and XRD
whereas buffered microbeads appeared to be a combination of
alginate powder and salt crystals when both analytical modalities
were used. Specifically, FTIR spectrum of non-buffered microbeads
closely resembled that of 16-day-old rat calvaria with characteristic
phosphate (900e1180 cm1) and amide I (1580e1750 cm1) peaks
[35]. Although, the broad phosphate peak in the non-buffered
microbeads does overlap with aryl-hydroxyl (1030e1085 cm1)
and carboxylic acid (915e995 cm1) groups found in the HEPES-
buffered microbeads and alginate powder, the disappearance of
alginate peaks found at lower frequencies, the low intensities of the
amide I and II peaks (1405e1420, 1600e1690 cm1) in the non-
buffered samples, and the XRD spectra suggest the formation ofhydroxyapatite. To confirm these findings, the Ca/P ratio for non-
buffered alginate was found to be 1.6  0.4, which closely matches
hydroxyapatite found in bone [36]. Non-buffered microbeads also
had traces of Mg, which has been associated with facilitating the
formation of calcified pathological cardiovascular deposits [37].
HEPES-buffered microbeads only had traces of calcium left, sug-
gesting that these samples were starting to be reabsorbed. The
presence of sulfur and higher content of carbon in HEPES-buffered
microbeads compared to non-buffered samples suggest levels of
tissue incorporation, which was also confirmed with histology.
More studies though are needed to determine the ability of
injectable microbeads to be used for tissue replacement or
regeneration.
Cell-mediated mineralization is a complex process, and it is
probable that multiple factors contribute to alginate calcification
and its inhibition. It is not completely clear why buffering the
calcium chloride bath with HEPES at a pH slightly below physio-
logical levels (7.3) or washing and storing alginate microbeads in
basal DMEM would prevent mineralization. Hydroxyapatite does
not form de novo at pH less than 6.8 [25]. More soluble calcium
phosphate phases form at lower pH values, hence the kinetics for
hydroxyapatite mineral deposition would be lessened at the lower
pH. It is possible that washing and storing microbeads in DMEM
Fig. 5. FTIR. Spectra of (A) non-buffered microbeads after 5 weeks in vivo, (B) buffered microbeads after 5 weeks in vivo, (C) HEPES powder used to buffer the crosslinking solution,
and (D) alginate powder used to make the microbeads.
Fig. 6. XRD. Spectra of HEPES powder used to buffer the crosslinking solution, alginate
powder used to make the microbeads, buffered microbeads after 5 weeks in vivo, NaCl
from the database, non-buffered microbeads after 5 weeks in vivo, and hydroxyapatite
from the database.
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inhibited growth of any hydroxyapatite nuclei in a similar manner
to how salivary proteins in supersaturated saliva prevent calcium
phosphate mineral precipitation by adsorbing active sites of crys-
tallite surfaces [25]. However, this explanation does not explain
why non-buffered microbeads that were injected in DMEM still
calcified. It is likely that making microbeads in HEPES-buffered
calcium chloride at this lower pH and subsequent washing and
storage in media was more effective than non-buffered saline alone
in removing excess calcium ions and preventing hydroxyapatite
nuclei from forming. Additionally, it has been shown that HEPES
binds calcium ions with a maximum apparent binding of
1.24  0.001 mmol of Ca2þ/L by HEPES at 10 mM and pH 7.39 [38].
Although alginate microbead calcification did not strongly
depend on the delivery method, delivery site, the presence of cells,
or sex of the animal, biological factors can play a significant role in
mineralizing alginate constructs in vivo. When bone marrow
mesenchymal stem cells (MSCs) were treated with 107 dexa-
methasone and 10 ng/ml TGF-b1 for more than 1 week, these cells
were able to mineralize alginate scaffolds in vivowhereas scaffolds
with cells treated for only 1 day had no apparent calcification [21].
Osteogenic-induced adipose stem cells are able to calcify collagen
scaffolds both in vitro and subcutaneously [39], and alginate
microbeads containing a combination of osteoprogenitor and
endothelial cells have been shown to mineralize in a metaphyseal
femoral bone defect [40]. The final adipose stem cells concentration
in our alginate microbeads is similar to MSC-seeded alginate
constructs in Ma et al (2  106 cells/ml) [21] but significantly less
than the microencapsulated osteoprogenitor and endothelial cells
Table 3
EDS calculated elemental composition of non-buffered and buffered in vivo samples.
Concentration [atomic %]a,b
C O Na Mg Al P S Cl Ca K
Non-buffered 34.0  4.3 47.2  2.0 <1 <1 1.2  0.4 6.3  0.8 <1 e 10.2  1.3 e
HEPES-buffered 41.6  1.0 27.5  1.9 14.3  0.7 e <1 1.15  0.1 <1 13.2  1.8 <1 <1
a The values should be evaluated with an error of approximately 2% relative.
b Elements that were not present in all measurements of the same sample were not included in the table (e.g., Si).
Fig. 7. SEM Images. (A) Lyophilized non-buffered microbeads after 5 weeks in vivo. (B) Lyophilized buffered microbeads after 5 weeks in vivo.
C.S.D. Lee et al. / Biomaterials 31 (2010) 4926e4934 4933in Grellier et al (20  106 cells/ml) [40]. Regardless, to better use
alginate microbeads for different tissue engineering strategies,
more studies are needed to understand the exact mechanisms
regulating in vivo mineralization of alginate.
Natural biomineralization systems and previous in vitro exper-
iments have suggested that crystal nucleation and growth from
organic templates occurs on surfaces that expose repetitive
patterns of anionic groups [36,41]. These negatively charged groups
concentrate and create local supersaturation of inorganic cations,
which leads to oriented nucleation of crystal formation. Alginate is
a co-polymer with negatively charged blocks of (1-4)-linked
b-D-mannuronate and (1-4)-linked a-L-guluronate residues. This
structure may allow alginate polysaccharide chains to facilitate
controlled calcification for bone tissue engineering. Peptide-
amphiphile nanofibers modified with negatively charged peptides
rich in phosphoserine groups have been shown to create
hydroxyapatite in vitro that was aligned in the same manner as
observed in bone [36]. Injectable, crosslinked-alginate that can
then mineralize in situ without the presence of other biological or
chemical factors may present an advantage over pre-mineralized
scaffolds or bone morphogenetic proteins in that it avoids adverse
immune responses, limits systemic side effects, and is minimally-
invasive for simple orthopaedic and reconstructive applications.
However, in addition to hydroxyapatite formation and alignment,
bone tissue engineering via mineralized alginate must also form
constructs with high porosity and collagen content, osteo-
conductive properties, bioactivity, and mechanical integrity in
order for this method of repair to be feasible.5. Conclusion
To understand the mechanism behind alginate calcification and
to develop ways to regulate it, studies in vitro and in vivo were
performed. Non-buffered calcium crosslinked alginate beads
placed in a phosphate buffered bath sequestered the surrounding
phosphate and calcified, forming traces of hydroxyapatite. Non-
buffered calcium crosslinked alginate microbeads with or without
ASCs also mineralized when implanted subcutaneously or intra-
muscularly or injected subcutaneously after 1e6 months. Moreextensive analysis with microCT, FTIR, XRD, and EDS showed that
the 1.6  0.4 Ca/P ratio of the mineral formed closely matched
hydroxyapatite found in bone. Incorporating bisphosphonate hel-
ped regulate alginate calcification whereas using barium chloride
as the crosslinking agent eliminated calcification. Buffering the
crosslinking solution at pH 7.3 while washing and storing samples
in basal media prior to implantation also eliminated calcification in
vivo. This study effectively showed that calcium throughout the
alginate is responsible for bulk hydroxyapatite formation and
developed methods to partially regulate and eliminate alginate
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